Mads Krogsgaard Thomsen resigns from Novo Nordisk

Novo Nordisk's EVP and chief science officer, Mads Krogsgaard Thomsen, is stepping down from his position, effective at the end of this month. His replacement is already settled.

Photo: Gregers Tycho/ERH

Mads Krogsgaard Thomsen is resigning form his role as executive vice president and chief science office after a long tenure at Novo Nordisk, the company informs in connection with the release of its annual financial report Wednesday morning.

Krogsgaard Thomsen, who is officially responsible for research and development at Novo Nordisk, will be leaving the firm towards the end of February this year to take over leadership of the Novo Nordisk Foundation as of March 1, where he will replace Birgitte Nauntofte, who has been the CEO since 2009.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Rumored GN purchase unlikely but not impossible, say analysts

A low value assessment, a high structural value, and no dominant shareholders make GN Group a reasonable investment case for international private equity firms and industrial players. But just how likely is it? Analysts reveal their best bets for what a GN acquisition could look like.

New CFO wants to shake things up at WSA

A mere month into her new job, Marianne Wiinholt, WS Audiology’s fifth chief financial officer since the firm was established through a merger in 2019, is heralding great structural changes.

Further reading

Related articles

Latest news

See all jobs